Candid Therapeutics
Rewriting the Biology of Autoimmune Disease
San Diego, United States · Founded 2024 · $875.0M raised
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- candidtx.com
- Total Funding
- $875.0M
- Last Round
- $505.0M Venture RoundMar 2026
- Rounds
- 2
About
Candid Therapeutics is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for autoimmune and inflammatory diseases. Founded in 2023 and backed by $370M in funding, the company is building a pipeline of next-generation immunology treatments targeting unmet medical needs in conditions such as lupus and myasthenia gravis.
Summary
Candid Therapeutics is a Biotech company based in San Diego, United States, founded in 2024. It has raised $875.0M in total across 2 rounds, most recently a $505.0M Venture Round round in Mar 2026.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...